Drug Profile
Research programme: cancer therapeutics - China Sky One Medical
Alternative Names: Endostatin - China Sky One Medical; Endothelin-1Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Harbin Medical University
- Developer China Sky One Medical
- Class Proteins
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in China
- 09 Mar 2011 Preclinical development is ongoing in China
- 08 Sep 2008 Preclinical trials in Cancer in China (unspecified route)